Real﹚orld data on emicizumab use and monitoring in paediatric severe haemophilia A (HA) patients are scarce. We therefore sought to evaluate safety, efficacy, and laboratory monitoring of emicizumab prophylaxis in a cohort of 40 children with severe HA, including 22 non﹊nhibitor patients and...
Camrelizumab in combination with fluorouracil or taxol plus platinum chemotherapy as first-line treatment of esophageal squamous cell carcinoma: A multicenter, open-label, prospective cohort study.doi:10.1200/JCO.2022.40.16_suppl.e160841e16084#Background:The introduction of immune checkpoint inhibitors...
Metronomic chemotherapy that can modulate tumor immunomicroenvironment is a potential partner for ICIs, which is also well-tolerated and low-cost.Methods:This was a phase Ib, open-label, single-center, multi-cohort study designed to evaluate the safety and efficacy of camrelizumab combined with ...
Additional longer‐term studies in a broader and larger cohort are required to better characterize CV safety.doi:10.1111/head.13684Tina M. OakesEli Lilly and Company Indianapolis IN USARichard KovacsSchool of Medicine Indiana University Indianapolis IN USANoah Rosen...
OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLCdoi:10.1016/j.jtho.2020.10.034M.M. AwadS.M. GadgeelH. BorghaeiA. Patnaik...
correction to rea1 wor1d effectiveness and safety of mepo1izumab in a mu1ticentric spanish cohort of asthma patients stratified by eosinophi1s the redes studyin any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the ...
COHORT analysisCANCER chemotherapyBackground: Neoadjuvant therapy is recommended to improve the prognosis of oesophageal squamous cell carcinoma (ESCC). As a PD-1 inhibitor developed in China, camrelizumab is more accessible and available for Chinese ESCC patients. Camrelizumab plus neoadjuvant ...
of adverse events [AEs]); secondary objective: clinical efficacy (changes in platelet count) and pharmacodynamic effect (changes in IgG levels).\nResults\nOf the 66 pts enrolled, 65 (98.5%) completed the study (one discontinued due to lack of efficacy, 4 mg/kg multiple-dose cohort). All...
85% of 3-month cohort patients received at least two doses of crizanlizumab, while 66% of the 6-month cohort received at least 4 doses of crizanlizumab. The median number of gap days between doses was 1 or 2.Conclusions66% of patients who receive crizanlizumab receive at least 4...
Methods: This single-arm retrospective cohort study used German patient-level prescription data. Patients aged ≥ 50 years, who received ≥ 1 brolucizumab prescription in one eye only (unilateral) and had a minimum of 12 months follow-up were included. Three cohorts were defined from the ...